Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3010832 | 1.00 | EPHX2 (0.35) | EPHX2KDM4EMEN1PKMKMT2A | |
| SCHEMBL3002773 | 0.84 | MEN1 (0.35) | EPHX2KDM4EMEN1PKMKMT2A | |
| SCHEMBL3002776 | 0.84 | MEN1 (0.35) | EPHX2KDM4EMEN1PKMKMT2A | |
| SCHEMBL2998105 | 0.78 | GRM2 (0.52) | EPHX2MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL2998103 | 0.78 | GRM2 (0.52) | EPHX2MEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL2999308 | 0.78 | EPHX2 (0.35) | EPHX2KDM4EMEN1PKMKMT2A | |
| SCHEMBL2999302 | 0.78 | EPHX2 (0.35) | EPHX2KDM4EMEN1PKMKMT2A | |
| SCHEMBL12356875 | 0.75 | HSD11B1 (0.35) | EPHX2ALDH1A1HTT | |
| SCHEMBL22788173 | 0.75 | MAPK1 (0.40) | L3MBTL1MAPK1 | |
| SCHEMBL14168157 | 0.75 | MAPK1 (0.40) | L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835426-B2 | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2125750-B1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-20100197675-A1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| EP-2125750-A2 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008106128-A2 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197675-A1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | EPHX2 1527/4885KDM4E 1377/4885MEN1 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.